...
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?
【24h】

Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

机译:是否应在食道癌的临床试验中常规考虑FDG-PET成像,以确保各部位之间方案的一致性?

获取原文
获取原文并翻译 | 示例
           

摘要

Considerable interest has been generated over the past decade with regard to the role of FDG-PET in staging as well as monitoring treatment response and radiotherapy planning in esophageal carcinoma. While accurate staging is essential for the selection of appropriate therapies, it also aids in correct prognostic stratification at a particular stage of the disease and in assessing the efficacy of a specific therapeutic regimen. Studies have documented that adding PET to the standard staging schemes improves the detection of stage IV disease in about 15-22% of cases [1-3].
机译:在过去的十年中,人们对FDG-PET在食管癌的分期以及监测治疗反应和放疗计划方面的作用产生了极大的兴趣。尽管准确的分期对于选择适当的治疗方法至关重要,但它也有助于在疾病的特定阶段进行正确的预后分层,并有助于评估特定治疗方案的疗效。研究表明,在标准的分期方案中添加PET可改善大约15-22%的病例的IV期疾病检测[1-3]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号